<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748084</url>
  </required_header>
  <id_info>
    <org_study_id>P110110</org_study_id>
    <secondary_id>2012-001636-56</secondary_id>
    <nct_id>NCT01748084</nct_id>
  </id_info>
  <brief_title>Rituximab in Systemic Sclerosis</brief_title>
  <acronym>RECOVER</acronym>
  <official_title>Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rituximab is effective in the treatment of&#xD;
      articular symptoms that occur in systemic sclerosis related polyarthritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a rare disease, characterized by microvascular and immunological&#xD;
      changes promoting extra-cellular matrix synthesis and widespread fibrosis. No treatment has&#xD;
      yet proven any ability to alter the disease fibrosing process. Specific auto-antibodies are&#xD;
      commonly found in this disease, and B lymphocytes are detected in cutaneous and pulmonary&#xD;
      infiltrates. Studies derived from murine models suggest a role for B lymphocyte blocking&#xD;
      strategies.&#xD;
&#xD;
      This lead to observational trials of B-cell therapy using rituximab in SSc that provided&#xD;
      encouraging results with no particular signal concerning tolerability. These trials included&#xD;
      heterogeneous patients with variable disease stages and different involved organs, and were&#xD;
      mostly unblinded, which preclude any definitive conclusion. However, they support the&#xD;
      continuous development of this therapeutic approach.&#xD;
&#xD;
      Taking up the early phase of the diffuse form of the disease is complicated by its rarity and&#xD;
      the heterogeneous progression of its visceral complications. This raises the question of&#xD;
      selecting a homogeneous group of patients to evaluate. The most convincing results for the&#xD;
      use of rituximab in autoimmune conditions have been found in rheumatoid arthritis. Joint&#xD;
      involvement is common in SSc with 75% of patients complaining about joint stiffness and pain,&#xD;
      and 30% presenting with synovitis, tenosynovitis, or flexion contractures. No specific&#xD;
      treatment has already addressed this issue, and it is generally proposed to use small doses&#xD;
      of oral corticosteroids in association with methotrexate, by analogy with rheumatoid&#xD;
      arthritis. We propose to evaluate the efficacy and safety of rituximab in SSc patients having&#xD;
      active arthritis despite first line treatment. Improving the articular involvement would&#xD;
      improve the quality of life f SSc patients and effectiveness of rituximab on skin and lung&#xD;
      fibrotic involvements will be assessed as secondary outcomes to estimate the overall effects&#xD;
      of this drug on SSc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2013</start_date>
  <completion_date type="Actual">April 18, 2016</completion_date>
  <primary_completion_date type="Actual">April 18, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of tender and swollen joints</measure>
    <time_frame>at 6 months</time_frame>
    <description>Measured out of 53 joints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life: SSc-HAQ</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Validated scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>modified Rodnan skin score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung fibrosis</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Pulmonary functional tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: SF-36</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Validated scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: Duruöz index</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <description>Validated scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (NaCl)</intervention_name>
    <description>Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone</description>
    <arm_group_label>NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systemic sclerosis fulfilling ACR or LeRoy's criteria&#xD;
&#xD;
          -  Active polyarthritis defined by &gt; 6/53 tender joints and &gt; 4/53 swollen joints&#xD;
&#xD;
          -  Ongoing first line therapy by prednisone (max 10 mg/d) and DMARDS (methotrexate,&#xD;
             leflunomide, azathioprine or mycophenolate)&#xD;
&#xD;
          -  Birth control if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overlap syndrome defined by clinical symptoms and positive specific auto-antibodies&#xD;
             (anti-CCP, anti-SSA, anti-DNA DNA anti-Sm) (Rheumatoid factors and anti-RNP are not&#xD;
             exclusion criteria)&#xD;
&#xD;
          -  Past therapy with Rituximab.&#xD;
&#xD;
          -  Severe and uncontrolled disease with renal, liver or haematological (neutropenia &lt;&#xD;
             1500 / mm3) failures, pulmonary (FVC &lt; 50%) or cardiac insufficiencies (LVEF &lt; 50%)&#xD;
&#xD;
          -  Not stable corticosteroid therapy or cyclophosphamide use in the last 6 months&#xD;
&#xD;
          -  Infectious risk : viral infections by B or C hepatitis or HIV, hypogammaglobulinemia&#xD;
             (&lt; 6 G/L), opportunistic infection or infection requiring IV antibiotics in the last 3&#xD;
             months.&#xD;
&#xD;
          -  Neoplastic solid tumor in the last 5 years&#xD;
&#xD;
          -  Drug or alcool abuses&#xD;
&#xD;
          -  Receiving patient or having received a biotherapy (anti-TNF, abatacept or tocilizumab)&#xD;
             in the last 3 months (possible inclusion beyond 3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick Allanore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hôpitaux de Paris, Université Paris Descartes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965. Epub 2010 Mar 25.</citation>
    <PMID>20338043</PMID>
  </reference>
  <reference>
    <citation>Simms RW, Lafyatis R. Rituximab: a potential therapeutic advance in scleroderma: what is the evidence? Rheumatology (Oxford). 2010 Feb;49(2):201-2. doi: 10.1093/rheumatology/kep421. Epub 2009 Dec 23.</citation>
    <PMID>20032221</PMID>
  </reference>
  <reference>
    <citation>Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010 Oct;40(2):127-36. doi: 10.1016/j.semarthrit.2009.09.003. Epub 2009 Dec 11. Review.</citation>
    <PMID>20004954</PMID>
  </reference>
  <reference>
    <citation>Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010 Feb;49(2):271-80. doi: 10.1093/rheumatology/kep093. Epub 2009 May 15.</citation>
    <PMID>19447770</PMID>
  </reference>
  <reference>
    <citation>Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009 Feb;60(2):578-83. doi: 10.1002/art.24249.</citation>
    <PMID>19180481</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>B-cell therapy, Anti-CD20 therapy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Lung fibrosis</keyword>
  <keyword>Randomised controled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

